TSHR agonists have the dual effects of increasing the efficacy of radioactive iodine therapy and potentially accelerating tumor progression; moreover, even after TSH stimulation, 10–20% of DTC fails to concentrate sufficient radioactive iodine for effective treatment (29). The gene discussed is TSHR; the disease is neoplasm.